Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: Effect on infections, CD4 cell counts and HIV suppression

AIDS

Volumn 14, Issue 4, 2000, Pages 387-395

  Angel, Jonathan B ^f   High, Kevin ^a   Rhame, Frank ^b   Brand, David ^c   Whitmore, James B ^d   Agosti, Jan M ^d   Gilbert, Mark J ^d   Deresinski, Stanley ^e  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b ABBOTT NORTHWESTERN HOSPITAL   (United States)

^c N Texas Ctr for AIDS/Clin Res   (United States)

^d AMGEN INC   (United States)

^e SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^f UNIVERSITY OF OTTAWA   (Canada)

Author keywords

AIDS; CD4 cell count; GM CSF; HIV; HIV RNA; Opportunistic infections

Indexed keywords

ABACAVIR; ADEFOVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION PAIN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NEUTROPHIL; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD; WEIGHT REDUCTION;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FEMALE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PLACEBOS; VIRAL LOAD;

EID: 0008762563     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200003100-00012     Document Type: Article

References (36)

1. 1. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
2. 2. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med 1999, 5:512-517.
3. 3. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication and viral persistence in patients on effective combination antiretroviral therapy. N Engl J Med 1999, 340:1605-1613.
4. 4. Hockett R, Kilby JM, Derdeyn CA, et al. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV-RNA. J Exp Med 1999, 189: 1545-1554.
5. 5. Wit FW, van Leeuwen R, Weverling GJ, et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999, 179:790-798.
6. 6. Fatkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11:F113-F116.
7. 7. Casado JL, Perez-Elias MJ, Antela A, et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 1998, 12:F131 -F135.
8. 8. Kaufmann GR, Duncombe C, Cunningham P, et al. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals. AIDS 1998, 12:1625-1630.
9. 9. Cohen OJ, Fauci AS. Transmission of multidrug-resistant human immunodeficiency virus - the wake-up call. N Engl J Med 1998, 339:341-343.
10. 10. Skowron G, Stein D, Drusano G, et al. The Safety and efficacy of granulocyte-macrophage colony-stimulating factor (sargramostin) added to Indinovir-or Ritonavir-based antiretroviral therapy: a randomized, double-blind, placebo-controlled trial. J Infec Dis 1999, 180:1064-1071.
11. 11. Brites C, Badaro R, Pedral-Sampiao, et al. Granulocyte-Macrophage-Colony-Stimulating-Factor (GM-CSF) reduces viral load and increases CD4 cell counts in individuals with AIDS. 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (1998) San Diego, California [abstract I-243]:440.
12. 12. Chun TW, Engel D, Mizell SB, et al. Effect of interleukin-1 on the pool of latently infected, resting CD4 + T cells in HIV-1-infected patients receiving highly active antiretroviral therapy. Nature Med 1999, 5:651 -655.
13. 13. Morrissey PJ, Bressler L, Park LS, Alpert A, Gillis S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol 1987, 139:1113-1119.
14. 14. Fischer HG, Frosch S, Reske K, Reske-Kunz AB. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J Immunol 1988, 141:3882-3888.
15. 15. Reid CD, Stackpoole A, Meager A, Tikerpae J. Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J Immunol 1992, 149:2681-2688.
16. 16. Stewart-Akers AM, Cairns JS, Tweardy DJ, McCarthy SA. Granulocyte-macrophage colony-stimulating factor augmentation of T-cell receptor-dependent and T-cell receptor-independent thymocyte proliferation. Blood 1994, 83: 713-723.
17. 17. Lopez AF, VVilliamson DJ, Gamble JR, et al. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest 1986, 78: 1220-1228.
18. 18. Esser R, Glienke W, Andreesen R, et al. Individual cell analysis of the cytokine repertoire inhuman immunodeficiency virus-1-infected monocytes/macrophages by a combination of immunocytochemistry and in situ hybridization. Blood 1998, 91: 4752-4760.
19. 19. Esser R, Glienke W, von Briesen H, et al. Differential regulation of proinflammatory and hematopoietic cytokines in human macrophages after infection with human immunodeficiency virus. Blood 1996, 88:3474-3481.
20. 20. Folks TM, Justement J, Kinter A, et al. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987, 238:800-802.
21. 21. Perno CF, Yarchoan R, Cooney DA, et al. Replication of human immunodeficiency virus in monocytes. Granulocyte/ macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med 1989, 169: 933-951
22. 22. Perno CF, Cooney DA, Currens MJ, et al. Ability of anti-HIV agents to inhibit HIV replication in monocyte /macrophages or U937 monocytoid cells under conditions of enhancement by GM-CSF or anti-HIV antibody. J Acquir Immune Defic Syndr Hum Retrovirol 1990, 6:1051-1055.
23. 23. Matsuda S, Akagawa K, Honda M, Yokota Y, Takebe Y, Takemori T: Suppression of HIV replication in human monocyte-derived macrophages induced by granulocyte/macrophage colony-stimulating factor. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:1031-1038.
24. 24. Di Marzio P, Mariani R, Tse J, Thomas EK, Landau NR. GM-CSF or CD40L suppresses chemokine receptor expression and HIV-1 entry in human monocytes and macrophages. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 37].
25. 25. Di Marzio P, Tse J, Landau NR: Chemokine receptor regulation and HIV type 1 tropism in monocyte-macrophages. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 14:129-138.
26. 26. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280: 78-86.
27. 27. Miller V, Mocroft A, Reiss P, et al. Relations among CD4 Lymphocyte Count Nadir, Antiretroviral Therapy, and HIV-1 Disease Progression: Results from the EuroSIDA study. Ann Intern Med 1999, 130:570-77.
28. 28. Autran B, Carcelain G, Tubiana R, et al. Effects of antiretroviral therapy on immune reconstruction. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract S44].
29. 29. Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 1999, 13:669-676
30. 30. Li TS, Tubiana R, Katlama C, et al. Long-lasting recovery in CD4 T-Cell function and viral load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998, 351:1682-1686.
31. 31. Till KJ, Burthem J, Lopez A, et al. Granulocyte-macrophage colony-stimulating factor receptor stage-specific expression and function on late B cells. Blood 1996, 88:479-486.
32. 32. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New Engl J Med 1997, 337: 725-733.
33. 33. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New Engl J Med 1997, 337:734-739.
34. 34. Deeks SG, Hecht FM, Swanson M, et al. HIV-RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS 1999, 13:F35-F43.
35. 35. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort story. Lancet 1999, 353:863-868.
36. 36. Rubio A, Gomez-Cano M, Puig T, et al. Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load. Antiviral Ther 1999, 4: 45-48.